Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy

被引：27

作者：

Bellati, Filippo ^{[1
]}

Napoletano, Chiara ^{[1
]}

Ruscito, Ilary ^{[1
]}

Liberati, Marco ^{[2
]}

Panici, Pierluigi Benedetti ^{[1
]}

Nuti, Marianna ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Rome, Italy

[2] Univ G dAnnunzio, Chieti, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 21期

关键词：

HER2-POSITIVE BREAST-CANCER; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; LAPATINIB GW572016; TUMOR-CELLS; E75; VACCINE; HER2/NEU; CYTOTOXICITY; INHIBITOR; TRIAL;

D O I：

10.1200/JCO.2010.28.6922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：E369 / E370

页数：2

共 39 条

[1]

LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].

AALTOMAA, S ;

LIPPONEN, P ;

ESKELINEN, M ;

KOSMA, VM ;

MARIN, S ;

ALHAVA, E ;

SYRJANEN, K .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864

[2]

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[3]

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming [J].

Atanackovic, Djordje ;

Altorki, Nasser K. ;

Cao, Yanran ;

Ritter, Erika ;

Ferrara, Cathy A. ;

Ritter, Gerd ;

Hoffman, Eric W. ;

Bokemeyer, Carsten ;

Old, Lloyd J. ;

Gnjatic, Sacha .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1650-1655

[4]

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 [J].

Benavides, Linda C. ;

Gates, Jeremy D. ;

Carmichael, Mark G. ;

Patel, Ritesh ;

Holmes, Jarrod P. ;

Hueman, Matthew T. ;

Mittendorf, Elizabeth A. ;

Craig, Dianna ;

Stojadinovic, Alexander ;

Ponniah, Sathibalan ;

Peoples, George E. .

CLINICAL CANCER RESEARCH, 2009, 15 (08) :2895-2904

[5]

Refining Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy [J].

Burstein, Harold J. ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5671-5673

[6]

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu [J].

Cooley, S ;

Burns, LJ ;

Repka, T ;

Miller, JS .

EXPERIMENTAL HEMATOLOGY, 1999, 27 (10) :1533-1541

[7]

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review [J].

Dawood, Shaheenah ;

Broglio, Kristine ;

Buzdar, Aman U. ;

Hortobagyi, Gabriel N. ;

Giordano, Sharon H. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :92-98

[8]

Eerola AK, 2000, CLIN CANCER RES, V6, P1875

[9]

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome [J].

Galon, Jerom ;

Costes, Anne ;

Sanchez-Cabo, Fatima ;

Kirilovsky, Amos ;

Mlecnik, Bernhard ;

Lagorce-Pages, Christine ;

Tosolini, Marie ;

Camus, Matthieu ;

Berger, Anne ;

Wind, Philippe ;

Zinzindohoue, Franck ;

Bruneval, Patrick ;

Cugnenc, Paul-Henri ;

Trajanoski, Zlatko ;

Fridman, Wolf-Herman ;

Pages, Franck .

SCIENCE, 2006, 313 (5795) :1960-1964

[10]

Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 [J].

Gennari, R ;

Menard, S ;

Fagnoni, F ;

Ponchio, L ;

Scelsi, M ;

Tagliabue, E ;

Castiglioni, F ;

Villani, L ;

Magalotti, C ;

Gibelli, N ;

Oliviero, B ;

Ballardini, B ;

Da Prada, G ;

Zambelli, A ;

Costa, A .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5650-5655

← 1 2 3 4 →